« Previous article
Bacterial and Viral ...

20th September 2021  Product update: rapidmicrobiology staff writer

Eight Gene SARS-CoV-2 Variant-Proof COVID-19 Test is CE-Marked

Thermo Fisher Scientific has launched its TaqPath COVID-19 RNase P 2.0 kit in Europe after receiving CE-marking. The newly designed test provides accurate results by compensating for current and future COVID-19 viral mutations.

The kit has been redesigned to detect active SARS-CoV-2 infections by identifying the presence of any one of eight gene targets from the virus. By surveying across multiple genes, the test can net accurate results even as mutations shift the genes they express. The TaqPath COVID-19 RNase P 2.0 kit uses an RNase P control to ensure sample integrity, quality, and extraction.

"SARS-CoV-2 is continuing to mutate, and this assay is the latest in our efforts to make sure our tests are future-proofed against those variants," said Manoj Gandhi, senior medical director for genetic testing solutions, Thermo Fisher Scientific. "With this product, we are offering customers the next generation of our COVID-19 diagnostic test that has in-built checks and balances in the face of emerging variants."

The TaqPath COVID-19 RNase P 2.0 kit uses a newly designed assay to assess nasopharyngeal and nasal swab samples to detect active COVID-19 cases. The test has a turnaround time of about three hours. The first-generation test, TaqPath COVID-19 CE-IVD RT PCR Kit, has been available with a CE-IVD mark since March 2020.

Request information using button provided below or visit ThermoFisher's dedicated TaqPath page.  



Date Published: 20th September 2021

Source article link: View

Note: This content has been edited by a rapidmicrobiology staff writer for style and content.

View full company details